Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4514-4521

  Lutgendorf, Susan K ^a   Cole, Steven ^d   Costanzo, Erin ^a   Bradley, Sarah ^a   Coffin, Jeremy ^b   Jabbari, Sarvenaz ^b   Rainwater, Kaitlin ^a   Ritchie, Justine M ^c   Yang, Maria ^e   Sood, Anil K ^e  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; HYDROCORTISONE; ISOPRENALINE; NORADRENALIN; PROPRANOLOL; VASCULOTROPIN;

ARTICLE; BEHAVIOR; CARCINOGENESIS; CONTROLLED STUDY; DISTRESS SYNDROME; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEDIATOR RELEASE; OVARY CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOCIAL SUPPORT; STATISTICAL SIGNIFICANCE; STRESS; TUMOR GROWTH;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ANTI-INFLAMMATORY AGENTS; EPINEPHRINE; FEMALE; HUMANS; HYDROCORTISONE; ISOPROTERENOL; NOREPINEPHRINE; OVARIAN NEOPLASMS; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 10744220803     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Andersen, B. L., Farrar, W. B., Golden-Kreutz, D., Kutz, L. A., MacCallum, R., Courtney, M. E., and Glaser, R. Stress and immune responses after surgical treatment for regional breast cancer. J. Nat. Cancer Inst., 90: 30-36, 1998.
2. Ben-Eliyahu, S., and Page, G. In vivo assesment of natural killer cell activity in rats. Prog. Neuroendocrine Immunol., 5: 199-214, 1992.
3. Fawzy, F. I., Cousins, N., Fawzy, N. W., Kemeny, M. E., Elashoff, R., and Morton, D. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch. Gen. Psychiatry., 47: 720-725, 1990.
4. Fawzy, F. I., Kemeny, M. E., Fawzy, N. W., Elashoff, R., Morton, D., Cousins, N., and Fahey, J. L. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch. Gen. Psychiatry., 47: 729-735, 1990.
5. Fawzy, F. I., Fawzy, N. W., Hyun, C. S., Elashoff, R., Guthrie, D., Fahey, J. L., and Morton, D. L. Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry., 50: 681-689, 1993.
6. Levy, S., Herberman, R., Lippman, M., D'Angelo, T., and Lee, J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav. Med., 17: 67-75, 1991.
7. McGregor, B., Antoni, M., Boyers, A., Alferi, S., Blomberg, B., and Carver, C. Effects of cognitive behavioral stress management on immune function and positive contributions among women with early stage breast cancer. J. Psychosom. Res., in press.
8. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Nat. Cancer Inst., 82: 4-6, 1990.
9. Kerbel, R. Tumor angiogenesis: past, present, and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
10. Folkman, J. Tumor angiogenesis. In: J. Mendelsohn, P. M. Howley, M. A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W.B. Saunders, 1995.
11. Lewin, M., Bredow, S., Sergeyev, N., Marecos, E., Bogdanov, A., and Weissleder, R. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int. J. Cancer, 83: 798-802, 1999.
12. McCourt, M., Wang, J., Sookhai, S., and Redmond, H. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch. Surg., 134: 1325-1332, 1999.
13. Inoue, M., Itoh, H., Tanaka, T., Chun, T. H., Doi, K., Fukunaga, Y., Sawada, N., Yamshita, J., Masatsugu, K., Saito, T., Sakaguchi, S., Sone, M., Yamahara, K. I., Yurugi, T., and Nakao, K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ. Arterioscler. Thromb. Vasc. Biol., 21: 560-566, 2001.
14. Wartiovaara, U., Salven, P., Mikkola, H., Lassila, R., Kaukonen, J., Joukov, V., Orpana, A., Ristimaki, A., Heikinheimo, M., Joensuu, H., Alitalo, K., and Palotie, A. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb. Haemost., 80: 171-175, 1998.
15. Brown, L., Detmar, M., Claffey, K., Nagy, J., Feng, D., Dvorak, A., and Dvorak, H. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS, 79: 233-269, 1997.
16. Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marme, D., and Gasti, G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and non-malignant disease. Cancer (Lond.), 85: 178-187, 1999.
17. Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., and Carson, L. F. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (Lond.), 80: 98-106, 1997.
18. Cooper, B. C., Ritchie, J. M., Broghammer, C. L. W., Coffin, J., Sorosky, J. I., Buller, R. E., Hendrix, M. J. C., and Sood, A. K. Preoperative serum vascular endothelial growth factor (VEGF) levels: significance in ovarian cancer. Clin. Cancer Res., 8: 3193-3197, 2002.
19. Abulafia, O., Triest, W., and Sherer, D. Angiogenesis in malignancies of the female genital tract. Gyn. Oncol., 72: 220-231, 1999.
20. Lutgendorf, S. K., Johnsen, E., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., and Sood, A. K. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer (Lond.), 95: 808-815, 2002.
21. Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. The expression of transforming growth factor-β-1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer (Lond.), 86: 1455-1462, 1999.
22. Cullinan-Bove, K., and Koos, R. D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with extrogen-induced increases in uterine capillary permeability and growth. Endocrinology, 133: 829-837, 1993.
23. Shweiki, D., Itin, A., Neufeld, G., Gitay-Goren, H., and Keshet, E. Patterns of expression of vascular endothelial growth factor(VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Investig., 91: 2235-2243, 1993.
24. Tonello, C., Giordano, A., Cozzi, V., Cinti, S., Stock, M. J., Carruba, M. O., and Nisoli, E. Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett., 442: 167-172, 1999.
25. Asano, A., Morimatsu, M., Nikami, H., Yoshida, T., and Saito, M. Adrenergic activation of vascular endothelial growth factor mRNA expression in rat brown adipose tissue: implication in cold-induced angiogenesis. Biochem. J., 328: 179-183, 1997.
26. Fredriksson, J. M., Lindquist, J. M., Bronnikov, G., and Nedergaard, J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/ cAMP/Protein Kinase A pathway involving Src but independently of Erk1/2. J. Biol. Chem., 275: 13802-13811, 2000.
27. Vandewalle, B., Revillion, F., and Lefebvre, J. Funtional beta-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol., 116: 303-306, 1990.
28. Marchetti, B., Spinola, P. G., Pelletier, G., and Labrie, F. A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. J. Ster. Biochem. Mol. Biol., 38: 307-320, 1991.
29. Chrousos, G. The concepts of stress and stress system disorders. JAMA, 267: 1244-1252, 1992.
30. Machein, M., Kullmer, J., Ronicke, V., Machein, U., Krieg, M., Damert, A., Breier, G., Risau, W., and Plate, K. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropath. Appl. Neurobiol., 25: 104-112, 1999.
31. Kawamura, A., Tamaki, N., and Kokunar, T. Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurol. Med Chir., 38: 633-638, 1998.
32. Nakane, T., Szentendrel, T., Stern, L., Virmani, M., Seely, J., and Kunos, G. Effects of IL-1 and cortisol on beta-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J. Immunol., 145: 260-266, 1990.
33. Kemp, V. H., and Hatmaker, D. D. Stress and social support in high risk pregnancy. Res. Nurs. Health., 12: 331-336, 1989.
34. Seeman, T. E., Berkman, L. F., Blazer, D., and Rowe, J. W. Social ties and support and neuroendocrine function: The MacArthur studies of successful aging. Ann. Behav. Med., 16: 95-106, 1994.
35. Antoni, M., Cruess, D., Wagner, S., Lutgendorf, S., Kumar, M., Ironson, G., Klimas, N., Fletcher, M., and Schneiderman, N. Cognitive behavioral stress management reduces anxiety and 24-hour urinary catecholamine output among symptomatic HIV-infected gay men. J. Consult. Clin. Psychol., 66: 31-45, 2000.
36. Antoni, M., Cruess, S., Cruess, D., Kumar, M., Lutgendorf, S., Ironson, G., Dettmer, E., Williams, J., Klimas, N., Fletcher, M., and Scheiderman, N. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann. Behav. Med., 22: 29-37, 2000.
37. Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M., Heidger, P. M., Buller, R. E., Seftor, R. E., and Hendrix, M. J. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol., 158: 1279-1288, 2001.
38. Sood, A., Fletcher, M. S., Gruman, L. M., Coffin, J. E., Jabbari, S., Khalkhali-Ellis, Z., Arbour, N., Seffor, E. A., and Hendrix, M. J. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res., 8: 2924-2932, 2002.
39. Hardman, J. G., Limbird, L. E., and Gilman, A. G. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10 ed. New York: McGraw Hill, 2001.
40. Stern, L., and Kunos, G. Synergistic regulation of pulmonary b-adrenergic receptors by glucocorticoids and interleukin-1. J. Biol. Chem., 263: 15876-15879, 1988.
41. Reid, S. D., Moon, T. W., and Perry, S. F. Rainbow trout hepatocyte β-adrenoceptors, catecholamine responsiveness, and effects of cortisol. Am. J. Physiol., 31: R794-R799, 1992.
42. Turner-Cobb, J., Sephton, S., Koopman, C., Blake-Mortimer, J., and Spiegel, D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom. Med. 62: 337-345, 2000.
43. Cruess, D., Leserman, J., Petitto, J., Golden, R., Szuba, M., Morrison, M., and Evans, D. Psychosocial-immune relationships in HIV disease. Sem. Clin. Neuropsychiatry, 6: 241-251, 2001.
44. Seeman, T., and McEwen, B. Impact of social environment characteristics on neuroendocrine regulation. Psychosom. Med., 58: 459-471, 1996.
45. Fawzy, F. I., Canada, A. L., and Fawzy, R. N. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch. Gen. Psychiatry., 60: 100-103, 2003.
46. Barton, D., Blanchard, D., Duan, C., Roberts, W., Cavanagh, D., DeCesare, S., and Djeu, J. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. J. Soc. Gynecol. Investig., 2: 762-771, 1995.
47. Garzetti, G., Cignitti, M., Ciavattini, A., Fabris, N., and Romanini, C. Natural killer cell activity and progression-free survival in ovarian cancer. Gynecol. Obstet. Investig., 35: 118-120, 1993.
48. Ioannides, C., Freedman, R., Platsoucas, C., Rashed, S., and Kim, Y. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol., 146: 1700-1707, 1991.
49. Lotzova, E., Savary, C., Freedman, R., and Bowen, J. Natural immunity against ovarian cancers. Comb. Immunol. Microbiol. Infect. Dis., 9: 269-275, 1986.
50. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., and Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 348: 203-213, 2003.
51. Kooi, S., Freedman, R. S., Rodriguez-Villanueva, J., and Platsoucas, C. D. Cytokine production by T-cell lines derived from tumor infiltrating lymphocytes from patients with ovarian carcinoma: tumor specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res., 12: 429-437, 1993.
52. Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D., and Freedman, R. S. Identification of an IL-10-producing HLA_DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine, protein expression and proliferation of autologous T cells. J. Immunol., 163: 6251-6260, 1999.
53. Rabinowich, H., Reichert, T. E., Kashii, Y., Gastman, B. R., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Investig., 101: 2579-2588, 1998.
54. Nakashima, M., Sonoda, K., and Watanabe, T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med., 5: 938-942, 1999.
55. Joseph, J., Biggemann, B., Zaenker, K. S., and Entschladen, F. The neurotransmitter γ-aminobutyric acid (GABA) is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res., 62: 6467-6469, 2002.